A phase II study of the efficacy and safety of an intensified schedule of azacytidine in intermediate-2 and high-risk patients with myelodysplastic syndromes: a study by the Groupe Francophone des Myelodysplasies (GFM)
Guardado en:
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Ferrata Storti Foundation
2019-04-01
|
| Colección: | Haematologica |
| Acceso en línea: | https://haematologica.org/article/view/8862 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|